Literature DB >> 12724763

Novel strategies for the treatment of sepsis.

Niels C Riedemann1, Ren-Feng Guo, Peter A Ward.   

Abstract

The history of therapeutic interventions in clinical trials for sepsis has been referred to as the "graveyard for pharmaceutical companies." That is now set to change, as research provides hope for new approaches that will be therapeutically effective in humans with sepsis.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12724763     DOI： 10.1038/nm0503-517

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  254 in total

Review 1.  Hematopoiesis sculpted by pathogens: Toll-like receptors and inflammatory mediators directly activate stem cells.

Authors:  Julie R Boiko; Lisa Borghesi
Journal:  Cytokine       Date:  2011-11-12       Impact factor: 3.861

Review 2.  Complement-induced impairment of the innate immune system during sepsis.

Authors:  Eric A Albrecht; Peter A Ward
Journal:  Curr Allergy Asthma Rep       Date:  2004-09       Impact factor: 4.806

Review 3.  Translational potential of systems-based models of inflammation.

Authors:  P T Foteinou; S E Calvano; S F Lowry; I P Androulakis
Journal:  Clin Transl Sci       Date:  2009-02       Impact factor: 4.689

4.  Single-stranded DNA oligoaptamers: molecular recognition and LPS antagonism are length- and secondary structure-dependent.

Authors:  J L Ding; S T Gan; B Ho
Journal:  J Innate Immun       Date:  2008-07-12       Impact factor: 7.349

Review 5.  Protective Role of Kallistatin in Vascular and Organ Injury.

Authors:  Julie Chao; Grant Bledsoe; Lee Chao
Journal:  Hypertension       Date:  2016-07-18       Impact factor: 10.190

6.  Toll-Like Receptors 2 and 4 Are Potential Therapeutic Targets in Peritoneal Dialysis-Associated Fibrosis.

Authors:  Anne-Catherine Raby; Chantal S Colmont; Ann Kift-Morgan; Jörg Köhl; Matthias Eberl; Donald Fraser; Nicholas Topley; Mario O Labéta
Journal:  J Am Soc Nephrol       Date:  2016-07-18       Impact factor: 10.121

7.  New approaches to sepsis: molecular diagnostics and biomarkers.

Authors:  Konrad Reinhart; Michael Bauer; Niels C Riedemann; Christiane S Hartog
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

8.  Ethyl pyruvate improves survival in awake hemorrhage.

Authors:  Bolin Cai; Michael Brunner; Haichao Wang; Ping Wang; Edwin A Deitch; Luis Ulloa
Journal:  J Mol Med (Berl)       Date:  2009-01-28       Impact factor: 4.599

9.  Inhibition of lipopolysaccharide-induced interferon regulatory factor 3 activation and protection from septic shock by hydroxystilbenes.

Authors:  Oanh Dang; Lorena Navarro; Michael David
Journal:  Shock       Date:  2004-05       Impact factor: 3.454

10.  Complement-induced Impairment of the Innate Immune System During Sepsis.

Authors:  Eric A Albrecht; Peter A Ward
Journal:  Curr Infect Dis Rep       Date:  2005-09       Impact factor: 3.725
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.